Medicinal cannabis gets blessing from on high

11 June 2019
cannabis

In the latest sign that the consumption of cannabis for medicinal purposes is being legitimized, the Church of England has reversed its previous policy of refusing to invest in schemes seeking to profit from the drug’s use.

The religious authority will now consider taking a punt on the sector, provided a company gets no more than 10% of revenue from selling recreational cannabis, the threshold it uses for most of its other ethical exclusions, such as tobacco, pornography, gambling and high-interest lenders, according to The Financial Times.

Around £12.6 billion ($16 billion) is invested in the church’s portfolios and among those now considered ethical enough to warrant consideration will be responsible producers of cannabis, which was legalized for medical use in the UK less than a year ago.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology